Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease

Lawrence J Jennings*, Frederick A. Smith, Kevin C. Halling, Diane L. Persons, Suzanne Kamel-Reid

*Corresponding author for this work

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Context.-Monitoring minimal residual disease by quantitative reverse transcription polymerase chain reaction has proven clinically useful, but as yet there are no Food and Drug Administration-approved tests. Guidelines have been published that provide important information on validation of such tests; however, no practical examples have previously been published. Objective.-To provide an example of the design and validation of a quantitative reverse transcription polymerase chain reaction test. Design.-To describe the approach used by an individual laboratory for development and validation of a laboratory-developed quantitative reverse transcription polymerase chain reaction test for BCR-ABL1 fusion transcripts. Results.-Elements of design and analytic validation of a laboratory-developed quantitative molecular test are discussed using quantitative detection of BCR-ABL1 fusion transcripts as an example. Conclusions.-Validation of laboratory-developed quantitative molecular tests requires careful planning and execution to adequately address all required analytic performance parameters. How these are addressed depends on the potential for technical errors and confidence required for a given test result. We demonstrate how one laboratory validated and clinically implemented a quantitative BCR-ABL1 assay that can be used for the management of patients with chronic myelogenous leukemia.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
JournalArchives of Pathology and Laboratory Medicine
Volume136
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Residual Neoplasm
Reverse Transcription
Polymerase Chain Reaction
United States Food and Drug Administration
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Guidelines

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

@article{7bca8dbcc4694f62be5b53bb0cd631be,
title = "Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease",
abstract = "Context.-Monitoring minimal residual disease by quantitative reverse transcription polymerase chain reaction has proven clinically useful, but as yet there are no Food and Drug Administration-approved tests. Guidelines have been published that provide important information on validation of such tests; however, no practical examples have previously been published. Objective.-To provide an example of the design and validation of a quantitative reverse transcription polymerase chain reaction test. Design.-To describe the approach used by an individual laboratory for development and validation of a laboratory-developed quantitative reverse transcription polymerase chain reaction test for BCR-ABL1 fusion transcripts. Results.-Elements of design and analytic validation of a laboratory-developed quantitative molecular test are discussed using quantitative detection of BCR-ABL1 fusion transcripts as an example. Conclusions.-Validation of laboratory-developed quantitative molecular tests requires careful planning and execution to adequately address all required analytic performance parameters. How these are addressed depends on the potential for technical errors and confidence required for a given test result. We demonstrate how one laboratory validated and clinically implemented a quantitative BCR-ABL1 assay that can be used for the management of patients with chronic myelogenous leukemia.",
author = "Jennings, {Lawrence J} and Smith, {Frederick A.} and Halling, {Kevin C.} and Persons, {Diane L.} and Suzanne Kamel-Reid",
year = "2012",
month = "1",
day = "1",
doi = "10.5858/arpa.2011-0136-OA",
language = "English (US)",
volume = "136",
pages = "33--40",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "1",

}

Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. / Jennings, Lawrence J; Smith, Frederick A.; Halling, Kevin C.; Persons, Diane L.; Kamel-Reid, Suzanne.

In: Archives of Pathology and Laboratory Medicine, Vol. 136, No. 1, 01.01.2012, p. 33-40.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease

AU - Jennings, Lawrence J

AU - Smith, Frederick A.

AU - Halling, Kevin C.

AU - Persons, Diane L.

AU - Kamel-Reid, Suzanne

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Context.-Monitoring minimal residual disease by quantitative reverse transcription polymerase chain reaction has proven clinically useful, but as yet there are no Food and Drug Administration-approved tests. Guidelines have been published that provide important information on validation of such tests; however, no practical examples have previously been published. Objective.-To provide an example of the design and validation of a quantitative reverse transcription polymerase chain reaction test. Design.-To describe the approach used by an individual laboratory for development and validation of a laboratory-developed quantitative reverse transcription polymerase chain reaction test for BCR-ABL1 fusion transcripts. Results.-Elements of design and analytic validation of a laboratory-developed quantitative molecular test are discussed using quantitative detection of BCR-ABL1 fusion transcripts as an example. Conclusions.-Validation of laboratory-developed quantitative molecular tests requires careful planning and execution to adequately address all required analytic performance parameters. How these are addressed depends on the potential for technical errors and confidence required for a given test result. We demonstrate how one laboratory validated and clinically implemented a quantitative BCR-ABL1 assay that can be used for the management of patients with chronic myelogenous leukemia.

AB - Context.-Monitoring minimal residual disease by quantitative reverse transcription polymerase chain reaction has proven clinically useful, but as yet there are no Food and Drug Administration-approved tests. Guidelines have been published that provide important information on validation of such tests; however, no practical examples have previously been published. Objective.-To provide an example of the design and validation of a quantitative reverse transcription polymerase chain reaction test. Design.-To describe the approach used by an individual laboratory for development and validation of a laboratory-developed quantitative reverse transcription polymerase chain reaction test for BCR-ABL1 fusion transcripts. Results.-Elements of design and analytic validation of a laboratory-developed quantitative molecular test are discussed using quantitative detection of BCR-ABL1 fusion transcripts as an example. Conclusions.-Validation of laboratory-developed quantitative molecular tests requires careful planning and execution to adequately address all required analytic performance parameters. How these are addressed depends on the potential for technical errors and confidence required for a given test result. We demonstrate how one laboratory validated and clinically implemented a quantitative BCR-ABL1 assay that can be used for the management of patients with chronic myelogenous leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84856026969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856026969&partnerID=8YFLogxK

U2 - 10.5858/arpa.2011-0136-OA

DO - 10.5858/arpa.2011-0136-OA

M3 - Article

C2 - 22208485

AN - SCOPUS:84856026969

VL - 136

SP - 33

EP - 40

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 1

ER -